Lupin gains FDA approval for two injectable products

Lupin Limited announced U.S. FDA approval for its Liraglutide Injection Single-Patient-Use Prefilled Pens and Glucagon for Injection vials.

Liraglutide Injection had estimated annual U.S. sales of $458 million, while Glucagon for Injection had estimated annual U.S. sales of $124 million. Both products will be manufactured at Lupin's Nagpur facility.